成人阻塞性睡眠呼吸暂停与 F2-异前列烷相关性的荟萃分析：持续气道正压通气。
Association of continuous positive airway pressure with F2-isoprostanes in adults with obstructive sleep apnea: a meta-analysis.
机构信息
Department of Otolaryngology, Quanzhou First Hospital Affiliated to Fujian Medical University, Dongjie Road, Licheng District, Quanzhou, 362000, Fujian province, People's Republic of China.
Department of Respiratory and Critical Care Medicine, Zhangzhou Affiliated Hospital of Fujian Medical University, No 59, Shenglixi Road, Xiangcheng District, Zhangzhou, 363000, Fujian province, People's Republic of China.
出版信息
Sleep Breath. 2019 Dec;23(4):1115-1122. doi: 10.1007/s11325-019-01795-6. Epub 2019 Feb 7.
PURPOSE
Obstructive sleep apnea (OSA) is associated with increased F2-isoprostanes, a reliable standard biomarker of oxidative stress. Treatment with continuous positive airway pressure (CPAP) is effective for all degrees of OSA. However, it remains unknown whether treatment with CPAP will decrease F2-isoprostanes. A meta-analysis was conducted to determine the effect of CPAP treatment on F2-isoprostanes among patients with OSA.
METHODS
The PubMed, Embase, Web of Science, and Cochrane library were searched before September, 2018. Eight articles assessing indices of F2-isoprostanes from various body fluids were identified. Pooled standardized mean difference (SMD) and weighted mean difference (WMD) were appropriately calculated through fixed or random effects models after assessing between-study heterogeneity.
RESULTS
A total of 4 studies with 108 patients were pooled for exhaled breath condensate (EBC) F2-isoprostanes; 3 studies with 93 patients were pooled for serum or plasma F2-isoprostanes; and 3 studies with 102 patients were pooled for urinary F2-isoprostanes. A significant decrease of EBC F2-isoprostanes was observed after CPAP treatment (WMD = 2.652, 95% CI = 0.168 to 5.136, z = 2.09, p = 0.036), as well as serum or plasma F2-isoprostanes and urinary F2-isoprostanes (SMD = 1.072, 95% CI = 0.276 to 1.868, z = 2.64, p = 0.008 and WMD = 85.907, 95% CI = 50.443 to 121.372, z = 4.75, p = 0.000, respectively).
CONCLUSIONS
This meta-analysis suggested that CPAP therapy was associated with a significant decrease in F2-isoprostanes in patients with OSA.
目的
阻塞性睡眠呼吸暂停（OSA）与氧化应激的可靠标准生物标志物 F2-异前列腺素升高有关。持续气道正压通气（CPAP）治疗对所有程度的 OSA 均有效。然而，CPAP 治疗是否会降低 F2-异前列腺素仍不清楚。进行了一项荟萃分析，以确定 CPAP 治疗对 OSA 患者 F2-异前列腺素的影响。
方法
在 2018 年 9 月之前，检索了 PubMed、Embase、Web of Science 和 Cochrane 图书馆。确定了 8 项评估各种体液中 F2-异前列腺素指标的文章。通过固定或随机效应模型适当计算了合并标准化均数差（SMD）和加权均数差（WMD），并在评估了研究间异质性后。
结果
共有 4 项研究（共 108 例患者）合并了呼气冷凝物（EBC）F2-异前列腺素；3 项研究（共 93 例患者）合并了血清或血浆 F2-异前列腺素；3 项研究（共 102 例患者）合并了尿 F2-异前列腺素。CPAP 治疗后 EBC F2-异前列腺素显著降低（WMD=2.652，95%CI=0.168 至 5.136，z=2.09，p=0.036），以及血清或血浆 F2-异前列腺素和尿 F2-异前列腺素（SMD=1.072，95%CI=0.276 至 1.868，z=2.64，p=0.008 和 WMD=85.907，95%CI=50.443 至 121.372，z=4.75，p=0.000）。
结论
这项荟萃分析表明，CPAP 治疗与 OSA 患者 F2-异前列腺素显著降低有关。
Zotero 插件